Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 15;12:15. doi: 10.1186/s12995-017-0161-x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s). 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 6 — Vit C protected against Cr (VI)-induced hepatotoxicity in vivo. All rats were given the drugs by gavage at a dose of 0.5 ml/100 g body weight daily for a week (seven consecutive days). Groups are indicated by pretreatment + treatment as follows: Con, Vit C, Cr (VI) (8.84 mg/kg.bw), Vit C+ Cr (VI) (8.84 mg/kg.bw), Cr (VI) (17.68 mg/kg.bw), and Vit C+ Cr (VI) (17.68 mg/kg.bw). a Effect of Vit C pretreatment on Cr (VI)-induced alterations in rat liver histology. b The chromium contents in stool, urine, liver and plasma. c AST and ALT activities. d GSH, SOD, and MDA levels. e Free radical scavenging capacity. Data represent mean ± SD. *p < 0.05, compared with control group. ^# p < 0.05, compared with the Cr (VI) alone treatment group